Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Galderma R&D: Clinical Trials & FDA Approval Profile

Galderma R&D (Global / Institutional) sponsors 31 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 6 active protocols (3 recruiting now), 23 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)6.5%
Median Closed Enrollment vs National (145 pts)280 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Galderma R&D
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)31
Active Pipeline (Recruiting Now)6 (3)
Completed vs Stopped Early23 / 2 (6.5%)
Median Closed Actual Enrollment280 participants
Physical Hospital Site Disclosure8.3% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the Galderma R&D Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI